Teva Pharmaceutical Industries Reports Strong Fourth Quarter Growth and Issues 2026 Guidance

Teva Pharmaceutical Industries reported fourth-quarter results that beat analyst estimates. The company also issued lower financial guidance for the 2026 year.

洞察:
Teva Pharmaceutical Industries Ltd. announced its fourth-quarter financial results on Wednesday, reporting an adjusted diluted profit that significantly exceeded analyst expectations. For the period from October to December, the company based in IL ILILearned $0.96 per diluted share excluding one-time items. This figure represents a notable increase from the $0.71 per share reported in the same quarter a year earlier.
The logo of Teva Pharmaceutical Industries is seen in Tel Aviv, Israel, February 19, 2019. REUTERS/Amir Cohen
The logo of Teva Pharmaceutical Industries is seen in Tel Aviv, Israel, February 19, 2019. REUTERS/Amir Cohen
IUX24

IUX24 提供深度財經、經濟與投資資訊,藉助 AI 發掘全球市場中最重要的信號。

IFZA Properties, Dubai Silicon Oasis, DSO-IFZA, Dubai, United Arab Emirates

Copyright IUX24 MEDIA - FZCO. 版權所有。

由 AI 驅動 • 精益求精

IUX24 是一個資訊與分析平台,提供新聞、市場數據、分析工具及 AI 驅動的功能,僅供資訊參考與教育用途。所提供的服務和資訊不構成投資建議、交易信號或經紀服務。投資涉及風險,用戶在作出投資決定前應審慎評估相關資訊。